Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08QBS
|
||||
| Former ID |
DNC009883
|
||||
| Drug Name |
MK-1925
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H21F3N4
|
||||
| Canonical SMILES |
CC1=C(N(N=C1CNC2CCC(C2)F)CCC#N)C3=CC(=CC(=C3)F)F
|
||||
| InChI |
1S/C19H21F3N4/c1-12-18(11-24-17-4-3-14(20)10-17)25-26(6-2-5-23)19(12)13-7-15(21)9-16(22)8-13/h7-9,14,17,24H,2-4,6,10-11H2,1H3
|
||||
| InChIKey |
LJTOZIFFXNLWEQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Kappa-type opioid receptor | Target Info | Inhibitor | [1] | |
| Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Opioid prodynorphin pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-1296072:Voltage gated Potassium channels | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| Hematopoietic Stem Cell Differentiation | |||||
| Potassium Channels | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32. Epub 2009 Jun 17.Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.